Vanda Pharmaceuticals stock barely budged after earnings, up about 0.5% to around US$5, even though the quarter underscored how hard the current build out is hitting the income statement. The headline is simple: revenue held around US$50.5m while the Q2 net loss widened to US$62.5m as spending on late stage trials and new launches weighed heavily.

Investors came into this print after a tough stretch, with the stock down about 20% over the past month. The key question now is how long the market will tolerate this profit squeeze while Vanda funds its pipeline and new products.

Concerned that Vanda Pharmaceuticals is leaning on heavy trial and launch spending while reporting a net loss this quarter? If you want stocks that pair research investment with stronger balance sheets, take a look at our list of solid balance sheet and fundamentals stocks (49 results).

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$50.5m vs. US$52.6m (revenue declined about 4% year on year)
• Net Loss (Q2 2026 vs. Q2 2025): US$62.5m vs. US$27.2m (loss widened significantly year on year)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$1.04 per share vs. loss of US$0.46 per share (per share loss increased year on year)
• Pipeline Scale (Trailing 12 Months to Q4 2025): 3 products in Phase I, 3 in Phase II, 8 in Phase III, 6 in pre registration (reflects a broad late stage development portfolio)

Prefer clear visuals instead of another wall of earnings tables and loss figures? See Vanda Pharmaceuticals' overall financial picture, including a visual breakdown of its balance sheet strength, in the company report for Vanda Pharmaceuticals.

Vanda bull case hinges on Fanapt and launch leverage

Bulls argue that Vanda Pharmaceuticals can use Fanapt growth and the launch engine around NEREUS and BYSANTI to spread fixed costs and support higher quality revenue. Q2 and first half numbers partly back that up. Fanapt net sales reached US$36m in Q2, up 23% year on year, with total prescriptions up 31% and new prescriptions up 32%. Since the bipolar I expansion, Fanapt total prescriptions are up 62% and new prescriptions are up a very large multiple versus Q2 2024. That is exactly the type of volume milestone this thesis needed. NEREUS contributed US$1m in H1 revenue with US$15.2m shipped to wholesalers, although US$12.6m is still constrained and not yet recognized. The reiterated 2026 revenue guidance and planned BYSANTI launch in the second half of 2026 support the idea of a broader commercial platform taking shape.

Bear case on losses, concentration and HETLIOZ pressure

Bears focus on widening losses, heavy cash burn and dependence on a few products. Q2 results give that view real support. Revenue slipped 4% year on year to US$50.5m while the net loss more than doubled to US$62.5m. Operating expenses in the first half rose about US$34m year on year to US$216.3m and management expects 2026 cash burn to be higher than 2025 even with US$170m of cash at 30 June 2026. HETLIOZ net sales fell 66% year on year in Q2 to US$5.6m as generic competition and destocking hit hard, underlining revenue concentration risk and competitive pressure. The company also recognized only US$1m of NEREUS revenue in H1 while most wholesaler stocking remains constrained, which means new launches are not yet offsetting the margin drag from higher R&D and SG&A and declining legacy products.

Compare Vanda Pharmaceuticals' push to scale Fanapt and launch NEREUS and BYSANTI with what institutions are actually penciling in for the stock. See the consensus price target analysis for Vanda Pharmaceuticals to check whether Wall Street price targets line up with that growth story.

Stay Ahead Of Your Next Move

If the mix of widening losses and Fanapt driven growth potential at Vanda Pharmaceuticals has your attention, register for free with Simply Wall St and add it to your Watchlist to monitor share price against fair value and watch how the story develops. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on the most important updates to your holdings. For a broader perspective on what other investors are seeing in Vanda Pharmaceuticals, join the conversation in the Community. By spotting hidden catalysts and risks early, you can make faster, better informed decisions and stay ahead of the market.

Seeking Alternatives Beyond Vanda Pharmaceuticals

Fresh stock ideas can move from quiet build up to sudden breakout while most investors are caught watching yesterday's winners. Scan for under the radar setups before the momentum is gone and act now.

• Spot resilient businesses that hold up when others wobble by scanning our curated 78 resilient stocks with low risk scores. This can help you identify potential opportunities before the market prices that resilience into every chart.
• Consider potential upside from rising electricity demand as AI and electrification reshape grids by tracking hand picked 36 power grid technology and infrastructure stocks. These may catch momentum before they draw broader attention.
• Position for the next leg of automation by reviewing carefully filtered 36 robotics and automation stocks. Many of these operational workhorses may still be under followed by a wide range of investors.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.